Watch Bactiguard Holding AB (publ) for free: we tell you when fair value or trend changes.

Bactiguard Holding AB (publ) (BACTI-B) fair value: what the stock is really worth

As of Oct 19, 2026: fair value (intrinsic value) of Bactiguard Holding AB (publ) stock SEK 13.17, price SEK 15.45, upside -14.8%, quality 49 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · SE · ISIN SE0005878741

Thin data Oct 3, 2026

Bactiguard Holding AB (publ)

BACTI-B · ST

Weak valuationQuality is weak on top of the rich price.

Our calculation puts a fair price 15% below what the stock costs today.

Low debt

Quality 49/100

Mixed Growth (revenue 5y +4.6 %/yr in SEK)

Fair value kr 13.17 · Overvalued (−14.8%)

Loss-making · -4.2% net margin (TTM)

Negative free cash flow

Trails peers (4/11)

Narrow moat 16/100 · thin data

Thin data

26 models, one by oneBear kr 7.24 to bull kr 17.42 Growth analysisrevenue history, year by year Quality 49/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Bactiguard Holding AB (publ) for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range kr 14.10 – kr 192.00 · fair‑value band kr 7.24 – kr 17.42 · the kr 15.45 price screens above the kr 13.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 3, 2026.

Follow Bactiguard Holding AB (publ) in your weekly email

Every Wednesday you see whether Bactiguard Holding AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas.

Show moreShow less

The company also has a portfolio of wound management products, such as Hydrocyn Aqua, an antimicrobial solution and gel for acute, chronic, and infected wounds; and surgical sutures comprising non-absorbable, natural absorbable, synthetic absorable, and specialty sutures.

It also operates through license partnerships with global MedTech companies that apply the technology to medical devices and sell them under own brand and co-branded.

The company has licensed partnership with Becton, Dickinson & Company for urinary catheter bardex IC and lubrisil IC; Well Lead Medical for catheters and tubes; and Zimmer Biomet for orthopedic trauma implants.

It operates in the United States, Sweden, Malaysia, India, Bangladesh, Indonesia, the Kingdom of Saudi Arabia, and internationally. The company was founded in 2005 and is headquartered in Stockholm, Sweden.

Stock analysis

Bactiguard Holding AB (publ) (BACTI-B) currently trades at kr 15.45, while our model-based Fair Value estimate is kr 13.17, 14.8% below the price, so the stock looks overvalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of kr 17.59 per share, and 1 of the 3 models we run sit above the kr 15.45 price.

Bear case: the Multiples group reads lowest at kr 13.17, and 2 of the 3 models stay below the price. Data coverage for this calculation is low.

Scenario range: kr 7.24 (bear) to kr 17.42 (bull), the price of kr 15.45 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Bactiguard Holding AB (publ) reported revenue of 216M SEK in FY2025 versus 169M SEK in FY2021, a compound +6.2%/yr. Reported net income was −7.8M SEK in FY2025.

Key figures

Market cap 541M SEK (≈ $54.6M) Micro · P/S ratio 2.74 · EPS (TTM) kr −0.2400 · Net margin −4.2% · Return on equity −2.9% · Return on assets (EBIT) −7.8% · Operating margin −9.6% · Revenue (TTM) 207M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (low confidence).

What moves the price

The share trades about 22% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −15%, BACTI-B screens richer than that median.

Fair Value models

Bear kr 7.24 Fair Value kr 13.17 Bull kr 17.42

Price kr 15.45 · Upside -14.8%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

Owner Earnings kr 7.24 kr 17.59 kr 36.81 71

EV/EBITDA kr 8.92 kr 13.17 kr 17.42 66

NCAV (Graham) kr 0.2300 kr 0.3100 kr 0.4600 54

All 3 models by family

DCF Models

Owner Earnings kr 7.24 kr 17.59 kr 36.81 71

Multiples

EV/EBITDA kr 8.92 kr 13.17 kr 17.42 66

Asset-Based

NCAV (Graham) kr 0.2300 kr 0.3100 kr 0.4600 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 21

How much profit the company makes from its sales and capital

Quality Growth 59

Are margins and returns getting better?

Cashflow 6

Do the profits arrive as real cash?

Financial strength 49

Debt, balance sheet and risk of trouble

Investment 99

Does it invest with discipline instead of growing at any price?

Low Volatility 52

How calm the share price moves, does not count

Momentum 28

Price trend of the last 3 to 12 months, does not count

Near the 52-week high 18

Distance to the 52-week high, does not count

New shares 82

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 8/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

−11.4%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−1.2%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+4.6%

Start year 2020 (pandemic). Over 10 years: +5.1% a year

Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+3.4%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−12.7% (2020) → −4.4% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

BACTI-B screens overvalued: fair value 15% below the price. Compare with Abbott Laboratories, →

Compare Bactiguard Holding AB (publ) with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 326 stocks

Beats the industry median on 4/10 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 49 · Below median

Fair Value upside −14.8% · Above median

Profitability

Return on assets −1.4% · Below median

Net margin (12 months) −4.2% · Below median

Operating margin (12 months) −9.6% · Bottom 25%

Growth and dividend

Revenue growth (quarter YoY) 11.9% · Above median

Balance sheet

Debt / equity 0.38× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.72× · Cheaper than median

P/S (12 months) 2.62× · Cheaper than median

EV/EBITDA 19.6× · Pricier than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)14 · sector 10

FUTURE (revenue growth)60 · sector 33

PAST (return on equity)0 · sector 16

HEALTH (low debt)81 · sector 98

DIVIDEND (yield)0 · sector 37

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Stryker Corporation SYK	$282.60	$310.86	+10%	vs BACTI-B
Boston Scientific Corporation BSX	$43.00	$47.30	+10%	vs BACTI-B
DexCom, Inc DXCM	$85.98	$94.58	+10%	vs BACTI-B
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥166.00	¥182.60	+10%	vs BACTI-B
GE HealthCare Technologies Inc GEHC	$65.74	$70.37	+7%	vs BACTI-B
Edwards Lifesciences Corporation EW	$86.60	$81.94	−5%	vs BACTI-B
Siemens Healthineers AG SHL	€41.45	€35.19	−15%	vs BACTI-B
Abbott Laboratories, ABT	$102.61	$74.79	−27%	vs BACTI-B
Medtronic plc MDT	$91.93	$65.61	−29%	vs BACTI-B
Koninklijke Philips N.V PHIA	€22.18	€15.23	−31%	vs BACTI-B

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bactiguard Holding AB (publ) · Fair Value
kr 13.17 −15%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/BACTI-B" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Bactiguard Holding AB (publ) · Fair Value</span><br><b style="font-size:20px">kr 13.17</b> <span style="color:var(--red);font-weight:700;font-size:14px">−15%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Bactiguard Holding AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/BACTI-B

Frequently asked questions

Is Bactiguard Holding AB (publ) (BACTI-B) overvalued or undervalued?

As of Oct 3, 2026, our model estimates a fair value of kr 13.17 versus a price of kr 15.45, about −15% upside (overvalued).

What is the fair value of BACTI-B?

Our model-based fair value for Bactiguard Holding AB (publ) is kr 13.17 (as of Oct 3, 2026), built from audited fundamentals. The current price: kr 15.45.

What is the quality score of BACTI-B?

Bactiguard Holding AB (publ) has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Bactiguard Holding AB (publ) (BACTI-B)?

Our model-based price target is the fair value of kr 13.17 (as of Oct 3, 2026) from 3 valuation models. Cautious scenario kr 7.24, optimistic scenario kr 17.42. It is a calculation from audited fundamentals, not an analyst target.

What is the Bactiguard Holding AB (publ) stock forecast for 2026?

Our models put fair value at kr 13.17, about −15% upside versus a price of kr 15.45 (overvalued). Cautious scenario kr 7.24, optimistic scenario kr 17.42. The calculation is refreshed regularly with new filings.

What is the revenue of Bactiguard Holding AB (publ) (BACTI-B)?

Bactiguard Holding AB (publ) reported trailing-twelve-month revenue of about 207M SEK (latest available figure, as of Oct 3, 2026).

What is the intrinsic value of Bactiguard Holding AB (publ) (BACTI-B)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bactiguard Holding AB (publ) it is kr 13.17 per share (as of Oct 3, 2026), against a price of kr 15.45. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).

Is Bactiguard Holding AB (publ) stock overvalued or undervalued in 2026?

As of Oct 3, 2026, BACTI-B trades above its calculated fair value: price kr 15.45, fair value kr 13.17, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of BACTI-B?

No. The price is what the market pays today (kr 15.45); the fair value is what the company's own numbers justify (kr 13.17). For Bactiguard Holding AB (publ) the two are kr 2.28 per share apart. That gap is exactly why we show both numbers side by side.

How much is Bactiguard Holding AB (publ) worth?

The market values Bactiguard Holding AB (publ) at about 541M SEK (market capitalisation, as of Oct 3, 2026). Per share that is kr 15.45; our models calculate a fair value of kr 13.17 per share.

What do the bullish and bearish scenarios say about BACTI-B?

Our models span a range for Bactiguard Holding AB (publ): cautious scenario kr 7.24, base kr 13.17, optimistic kr 17.42 per share (as of Oct 3, 2026, price kr 15.45). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Bactiguard Holding AB (publ) (BACTI-B)?

Balance-sheet figures for Bactiguard Holding AB (publ) (as of Oct 3, 2026): return on equity −2.9%, debt of 0.38 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.

How far is BACTI-B from its 52-week high?

Bactiguard Holding AB (publ) trades at kr 15.45, about 22% below its 52-week high of kr 19.90 and 10% above the low of kr 14.10 (as of Oct 19, 2026). Distance from the high says nothing about value: that is what the fair value of kr 13.17 is for.

Which stocks are comparable to Bactiguard Holding AB (publ)?

From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Bactiguard Holding AB (publ) stock attractive at the current price?

The data as of Oct 3, 2026: price kr 15.45, calculated fair value kr 13.17 (−15%), Quality Score 49/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of BACTI-B calculated?

We run Bactiguard Holding AB (publ) through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 13.17, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.9 % above its aggregate fair value. Bactiguard Holding AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Bactiguard Holding AB (publ) (BACTI-B)?

The closing price on Oct 19, 2026 was kr 15.45. Our model-based fair value is kr 13.17, about −15% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Bactiguard Holding AB (publ) right now?

Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 7.24 to kr 17.42) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Bactiguard Holding AB (publ)

How large is the market capitalisation of Bactiguard Holding AB (publ) (BACTI-B)?

The market capitalisation of Bactiguard Holding AB (publ) is 541M SEK (≈ $54.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Bactiguard Holding AB (publ) (BACTI-B)?

The price-to-sales ratio of Bactiguard Holding AB (publ) is 2.74 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Bactiguard Holding AB (publ) (BACTI-B)?

Earnings per share at Bactiguard Holding AB (publ) are kr −0.2400. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Bactiguard Holding AB (publ) (BACTI-B)?

The net margin of Bactiguard Holding AB (publ) is −4.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Bactiguard Holding AB (publ) (BACTI-B)?

The return on equity (ROE) of Bactiguard Holding AB (publ) is −2.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Bactiguard Holding AB (publ) (BACTI-B)?

On an EBIT basis the return on assets of Bactiguard Holding AB (publ) is −7.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Bactiguard Holding AB (publ) (BACTI-B)?

The operating margin of Bactiguard Holding AB (publ) is −9.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Bactiguard Holding AB (publ) (BACTI-B)?

Revenue at Bactiguard Holding AB (publ) is growing +11.9% versus a year earlier (3y avg −1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does Bactiguard Holding AB (publ) (BACTI-B) generate?

The free cash flow of Bactiguard Holding AB (publ) is −7.2M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does Bactiguard Holding AB (publ) (BACTI-B) carry?

The net debt of Bactiguard Holding AB (publ) is 119M SEK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Bactiguard Holding AB (publ) in the live analysis

One click puts Bactiguard Holding AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.